Summary The overexpression of the multidrug resistance (mdrl) gene and its product, P-glycoprotein (P-gp), is thought to limit the successful chemotherapy of human tumours. The mechanism by which mdrl gene 
The development of the multidrug resistance (MDR) phenotype in human tumours is thought to be a major obstacle to successful chemotherapy. The MDR phenotype is associated with increased expression of the mdrl gene (Roninson et al., 1984; Gros et al., 1986; Ueda et al., 1987) . This gene codes for a high molecular weight membrane glycoprotein of 170 kDa, P-gp (Juliano and Ling, 1976) . Expression of the mdrl gene and P-gp occurs commonly in tumours derived from normal tissues such as colon, liver, kidney, pancreas and adrenal gland that express the multidrug transporter intrinsically (Fojo et al., 1987; Thiebaut et al., 1987; Croop et al., 1989; Goldstein et al., 1989) . However, some tumours derived from non-mdrlexpressing tissues, such as acute non-lymphocytic leukaemia and neuroblastoma, express the mdrl gene and P-gp during tumour progression (Ma et al., 1987; Chan et al., 1991) . The mechanism by which these cells overexpress mdrl and P-gp is not fully understood.
Many genetic alterations occur within the cell during tumour progression. The tumour-suppressor gene p53 mutations are the most common genetic alterations (Levine et al., 1991; Vogelstein and Kinzler, 1992; Finlay, 1993; Harris and Hollstein, 1993) . Recent studies have demonstrated that mutations of p53 affect mdrl gene promoter activity (Chin et al., 1992; Zastawny et al., 1993) . On the other hand, the human homologue of the mdm2 gene coding a p53-binding protein has recently been cloned (Oliner et al., 1992) . The product of this gene is shown to act as a negative regulator of wild-type p53 protein and possesses oncogenic activity like mutant p53 (Hinds et al., 1990; Fakharzadeh et al., 1991; Momand et al., 1992; Barak et al., 1993) .
Recently, we have obtained evidence that a human glioblastoma cell line expressing P-gp also overexpresses MDM2 protein (unpublished data). Therefore, we wished to investigate whether the mdm2 gene is related to the expression of the mdrl gene and P-gp in tumour cells. In this study, we attempted to determine whether the mdm2 gene induces the expression of the mdrl gene and P-gp in human glioblastoma Materials and methods Tumour cells and mdm2 transfection Human glioblastoma U87-MG cells (RIKEN Cell Bank, Wako, Japan) were cultured in Dulbecco's modified Eagle medium (DMEM) (Nissui, Tokyo, Japan) supplemented with 10% heat-inactivated fetal calf serum (FCS) (GIBCO, Grand Island, NY, USA), 4 mM glutamine, 50 U/ml -'penicillin and 50 /ig/ml-' streptomycin. Stable mdm2-transfected cell clones were generated as described previously (Kondo et al., 1995) . Tumour cells were seeded at a density of 6 x 105 per 100 mm dish on day 1, and transfected on day 2 by the calcium phosphate method (Mammalian Transfection kit, Stratagene, La Jolla, CA, USA) with 10 jug of human mdm2 expression vector pCMV-MDM2 (kindly supplied by Dr B Vogelstein) (Oliner et al., 1992 (Oliner et al., , 1993 . On day 3, the cells were rinsed and refed with fresh medium. On day 4, the cells were trypsinised and seeded at 2 x 105 cells per 100 mm dish into G418 (300 Mgml-')-containing medium. After a one week period of incubation at 37°C, six G418-resistant colonies were cloned into medium with G418. The production of the MDM2 protein in tumour cells was assessed by immunoblotting using MAb to MDM2 (IF-2, Oncogene Science, NY, USA).
RNA extraction and Northern blot analysis Cytoplasmic RNA was extracted by the NP-40 lysis protocol (Ginsberg et al., 1990 Effect of mdm2 antisense on P-gp expression and VP-16/ doxorubicin-induced cytotoxicity in MDM2-U87-MG cells As shown in Figure 5 , MDM2-U87-MG cells treated with mdm2 antisense showed reduction in the levels of P-gp as well as MDM2 protein 48 h after adding antisense. On the other hand, mdm2 sense did not cause any reduction in P-gp and MDM2 expression (data not shown). There was too much scatter in the data from MTT growth inhibition assays with antisense for statistically significant differences to be observed. 
Discussion
In this study, we present data showing that the mdm2 gene induced the expression of the mdrl gene and P-gp in U87-MG cells, and subsequently, conferred resistance to apoptotic cell death induced by VP-16 and doxorubicin. MDR is caused by overexpression of P-gp that binds analogues of ATP (Schurr et al., 1989) and cytotoxic drugs (Safa et al., 1986) , exhibits ATPase activity (Sarkadi et al., 1992) , and serves as an ATP-conducting channel (Abraham et al., 1993) . P-gp appears to function as an energy-dependent transport pump capable of effluxing cytotoxic agents and thereby decreasing their intracellular concentration. Recent studies have demonstrated that the expression of P-gp may not only predict the response of individual tumours to specific cytotoxic agents but may also provide important criteria for determining successful chemotherapeutic protocols (Chabner and Wilson, 1991; Goldstein and Ozols, 1991) . Consequently, to evaluate the mechanisms regulating the expression of mdrl and P-gp has obvious clinical implications.
Chin et al. (1992) have recently indicated that the mdrl gene could be activated during tumour progression associated with mutations in p53 and ras. In addition, Zastawny et al. (1993) demonstrated that the wild-type p53 protein repressed P-gp-promoter activity, while mutant p53 enhanced it. Certainly, p53 mutations appear to be the most common genetic alterations in human tumours including malignant gliomas (Hollstein et al., 1991; Levine et al., 1991; Sidransky et al., 1992; Vogelstein and Kinzler, 1992; Finlay, 1993; Harris and Hollstein, 1993 (Momand et al., 1992; Olson et al.. 1993) , and inhibit p53 function by concealing the activation domain of p53 from the cellular transcription machinery (Oliner et al. 1993) . Taken together. we suggest that mdm2, besides possessing oncogenic activity (Fakharzadeh et al., 1991; Olson et al., 1993) , may have a further deleterious effect by providing the mechanism by which the mdrl gene and P-gp can be overexpressed in human tumours. Further experiments. however, are needed to determine whether increased mdm2 and P-gp expression are stable or transient phenomenona in the transfectant sublines. More recently, we demonstrated that MDM2 protein conferred resistance of human glioblastoma cells to non-P-gp drug. cisplatin-induced apoptosis (Kondo et al., 1995) . Therefore. our data do not allow assessment of the extent to which resistance in the transfectants was due to expression of MDM2 or P-gp. To discern between the two mechanisms. data would be needed on (1) cellular pharmacology of VP-16 and doxorubicin; or (2) the effects of anti-P-gp oligonucleotide treatment on resistance levels. Taken together. MDM2 may prevent chemotherapy-induced apoptosis. and subsequently., the suppression of MDM2 expression may become a novel approach for the successful treatment of tumours. 
